• Molecular NameOxatomide
  • SynonymNA
  • Weight426.564
  • Drugbank_IDN/A
  • ACS_NO60607-34-3
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)4.59
  • pkaN/A
  • LogD (pH=7, predicted)3.41
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-4.44
  • LogSw (predicted, AB/LogsW2.0)0.13
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors1
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds7
  • TPSA38.82
  • StatusN/A
  • AdministrationN/A
  • PharmacologyA piperazine antihistamine.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic. Major metabolic pathways of oxatomide were oxidative N-dealkylations at the piperazine nitrogens and at the benzimidazolone nitrogen in rats and man, and also aromatic hydroxylation at the benzimidazolone moiety in man.The main urinary metabolite of oxatomide is 2,3-dihydro-2-oxo-1H-benzimidazole-1-propanoic acid, resulting from the oxidative N-dealkylation at the 1-piperazine nitrogen.
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)LD50>1000 (ip)